Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains
- PMID: 7989587
- PMCID: PMC330060
- DOI: 10.1172/JCI117596
Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains
Abstract
IL-6 is an autocrine growth factor for U266 myeloma cells and their growth is inhibited by IFN-alpha or IL-6 mAb. We asked, therefore, whether IFN-alpha-induced growth inhibition involved IL-6. IFN-alpha and mAb against IL-6, the IL-6R alpha-(gp80) or beta-chain (gp130) potently inhibited U266 cells. Remarkably, this effect occurred despite IFN-alpha-augmented secretion of endogenous IL-6. However, examining the IL-6R revealed that IFN-alpha drastically curtailed expression of the IL-6R alpha- and beta-chain. This effect occurred on two different levels (protein and mRNA) and by two different mechanisms (directly and indirectly through IL-6). First, IFN-alpha, but not IL-6, greatly decreased gp80 and, to a lesser extent, gp130 mRNA levels which resulted in a loss of IL-6 binding sites. Second, IFN-alpha-induced IL-6 predominantly down-regulated membrane-bound gp130. IFN-alpha-mediated decrease of gp80 levels was not detected on IL-6-independent myeloma (RPMI 8226) or myeloid cells (U937). We conclude that IFN-alpha inhibited IL-6-dependent myeloma cell growth by depriving U266 cells of an essential component of their autocrine growth loop, a functional IL-6R.
Similar articles
-
Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines.Eur J Immunol. 1994 Jan;24(1):124-30. doi: 10.1002/eji.1830240119. Eur J Immunol. 1994. PMID: 8020547
-
IFN-alpha induces autocrine production of IL-6 in myeloma cell lines.J Immunol. 1991 Dec 15;147(12):4402-7. J Immunol. 1991. PMID: 1753108
-
Roles of protein phosphatase 1 and 2A in an IL-6-mediated autocrine growth loop of human myeloma cells.Cell Immunol. 1996 Mar 15;168(2):174-83. doi: 10.1006/cimm.1996.0064. Cell Immunol. 1996. PMID: 8640863
-
[Cytokines and lymphoplasmocytic proliferations: essential role of interleukin 6].Rev Prat. 1993 Feb 1;43(3):275-8. Rev Prat. 1993. PMID: 8502954 Review. French.
-
Cytokine network in human multiple myeloma.Hematol Oncol Clin North Am. 1992 Apr;6(2):273-84. Hematol Oncol Clin North Am. 1992. PMID: 1582974 Review.
Cited by
-
Interleukin-6-induced proliferation of human myeloma cells associated with CD45 molecules.Int J Hematol. 2003 Aug;78(2):95-105. doi: 10.1007/BF02983376. Int J Hematol. 2003. PMID: 12953802 Review.
-
Protein kinase ERK contributes to differential responsiveness of human myeloma cell lines to IFNalpha.Cancer Cell Int. 2002 Jul 8;2(1):9. doi: 10.1186/1475-2867-2-9. Cancer Cell Int. 2002. PMID: 12234375 Free PMC article.
-
Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients?Med Oncol. 2000 May;17(2):77-84. doi: 10.1007/BF02796202. Med Oncol. 2000. PMID: 10871813 Review.
-
Comparative Cell Surface Proteomic Analysis of the Primary Human T Cell and Monocyte Responses to Type I Interferon.Front Immunol. 2021 Feb 8;12:600056. doi: 10.3389/fimmu.2021.600056. eCollection 2021. Front Immunol. 2021. PMID: 33628210 Free PMC article.
-
Long-term survival in multiple myeloma: a single-center experience.Clin Exp Med. 2008 Sep;8(3):133-9. doi: 10.1007/s10238-008-0169-8. Epub 2008 Sep 13. Clin Exp Med. 2008. PMID: 18791685 Clinical Trial.